This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vollmer, J.
Right arrow Articles by Krieg, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vollmer, J.
Right arrow Articles by Krieg, A. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2004, p. 2314-2317, Vol. 48, No. 6
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.6.2314-2317.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Immunopharmacology of CpG Oligodeoxynucleotides and Ribavirin

Jörg Vollmer,1* Robert Rankin,1,{dagger} Hanna Hartmann,1 Marion Jurk,1 Ulrike Samulowitz,1 Tanja Wader,1 Andrea Janosch,1 Christian Schetter,1 and Arthur M. Krieg2

Coley Pharmaceutical, Langenfeld, Germany,1 Coley Pharmaceutical Group, Wellesley, Massachusetts 024812

Received 25 September 2003/ Returned for modification 2 December 2003/ Accepted 3 February 2004

To investigate their potential mechanisms of action, the nucleoside analogue ribavirin and a TLR9 agonist were compared. The CpG oligodeoxynucleotides (ODN) demonstrated strong TLR9-related Th1-type effects, and ribavirin appeared only to mediate signaling in TLR-transfected cells. CpG ODN represent a promising new type of therapeutic drug for hepatitis C or other infectious diseases.

* Corresponding author. Mailing address: Coley Pharmaceutical GmbH, Elisabeth-Selbert-Strasse 9, D-40764 Langenfeld, Germany. Phone: (49) 2173-3997-0. Fax: (49) 2173-3997-2399. E-mail: jvollmer{at}coleypharma.com.

{dagger} Present address: European Patent Office, Patentlaan 2, NL-2280 HV Rijswijk, The Netherlands.

Antimicrobial Agents and Chemotherapy, June 2004, p. 2314-2317, Vol. 48, No. 6
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.6.2314-2317.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Gish, R. G. (2006). Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother 57: 8-13 [Abstract] [Full Text]  
  • Senn, J. J., Burel, S., Henry, S. P. (2005). Non-CpG-Containing Antisense 2'-Methoxyethyl Oligonucleotides Activate a Proinflammatory Response Independent of Toll-Like Receptor 9 or Myeloid Differentiation Factor 88. J. Pharmacol. Exp. Ther. 314: 972-979 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»